Mentioning financial chance, and the general advantages of comprehensive growth, President John Kennedy when said, “A rising tide raises all boats.” As the COVID crisis fades, and economic activity begins returning to normal, we might be seeing simply such a situation.
The corporate earnings season, which is underway now, is clobbering expectations for the first quarter of 2021. We’ve seen reports from 121 S&P- noted companies, and so far earnings are up 45.3% year-over-year.
Weighing in from Oppenheimer, chief investment strategist John Stoltzfus kept in mind, “As the number of vaccines administered stateside has moved higher, organization and customer belief [have] broadly improved from completion of in 2015 … in the meantime the equity markets in our view reflect a continuing capitulation of a bearish summary of stocks and potential customers for the economy that has actually overstayed its welcome amongst many financiers … We continue to prefer equities in the current transitional environment.”
Taking Stoltzfus’s outlook into consideration, we wanted to take a more detailed look at 2 cent stocks scoring rave reviews from Oppenheimer. These tickers trading for less than $5 per share could gain over 100% in the next year, so state the company’s analysts. Utilizing TipRanks’ database, we found out what exactly makes both so engaging even with the threat included with these plays.
CASI Pharmaceuticals (CASI).
The first cent stock we’re taking a look at is a pharmaceutical company with one foot in each of the world’s biggest markets. CASI is based in both Beijing, China and Rockville, Maryland. The business is US in origin, with Chinese operations carried out by an entirely owned subsidiary. CASI has one drug readily available in the commercial market; Evomela has applications in both cell transplant procedures and the treatment of numerous myeloma, and has been available in China considering that 2019.
In addition to Evomela, CASI has an active pipeline, featuring 4 drug candidates in numerous phases of development– from preclinical to Phase 1 or 2 trials. CASI’s pipeline focuses on hematological oncology, with drug candidates under investigation as treatments for non-Hodgkin’s Leukemia, multiple myeloma, and AML, along with general strong growth applications. CASI’s line of product is developed for commercialization in the Chinese medical markets.
CNTC19, CASI’s most advanced program, has actually gotten a Development Treatment Designation from China CDE, due to success revealed by initial information in the Phase 1 study of security and efficacy for the treatment of relapsed B-cell severe lymphoblastic leukemia (B-ALL). The next step, a Phase 2 research study for patients with B-cell non-Hodgkin Lymphoma, is currently registering.
Likewise of note, CASI’s drug prospect BI-1206 showed prospective after a Phase 1/2a trial. The business believes that the drug has potential to restore activity of rituximab in clients with non-Hodgkin lymphoma, already treated with rituximab, who have fallen back. Additional trials are prepared for later this year.
On the monetary end, CASI reported for full-year 2020 revenue of $15 million, compared to $4.1 million in 2019. This was based primarily on sales of Evomela, and went beyond the formerly released guidance of $14 million for the year. The business ended up 2020 with $57.1 million in money on hand, and in March of this year, to raise capital, put over 15.8 million shares of common stock on the marketplace. The stock sale earned over $32 million prior to expenses.
Covering CASI for Oppenheimer, expert Leland Gershell believes that the current financing “strengthens CASI’s position as the company continues to assess chances to further expand its portfolio of distinguished oncology assets.”.
The analyst added, “We believe CASI is among a couple of openly traded biotech business positioned to attain success by targeting the burgeoning Chinese pharmaceutical market. Through a licensing-driven business design, the company continues to construct an oncology-focused portfolio of drug assets at all phases of advancement. Evomela is expected to grow 50%+ in 2021 and we believe the business’s CD19 CAR-T treatment for B-cell malignancies will end up being the preferred option in China within this competitive class.”.
In line with this bullish outlook, Gershell puts an Outperform (i.e. Buy) score on the stock, and his $5 cost target suggests an upside of 192% for the next 12 months. (To see Gershell’s performance history, click here).
In basic, the rest of the Street has a positive view of CASI. The stock’s Strong Buy status originates from the 3 Purchases issued over the previous three months. The stock is selling for $1.70 per share, and its typical price target of $4.10 recommends it has room for ~ 140% development in 2021. (See CASI stock analysis on TipRanks).
Vascular Biogenics (VBLT).
Shifting focus a little, from China to the US, we’ll look at Vascular Biogenics, a biopharma business establishing treatments for both cancer and immune/inflammatory diseases.
VBLT’s leading drug prospect is VB-111, an oncology drug being examined as a treatment for several solid tumors. This first-in-class gene therapy has applications for ovarian cancer, frequent glioblastoma, colon cancer, and thyroid cancer. In a Phase 1 trial, VB-111 was shown to be well-tolerated by over 300 cancer patients across those conditions. Additional successful trials included Stage 2 research studies that were tumor-specific for ovarian cancer, thyroid cancer, and persistent glioblastoma. The drug prospect is currently going through a Phase 3 study, OVAL, for platinum-resistant Ovarian Cancer. That research study has enrolled over 200 patients, and reveals high reaction rates in over 50% of the evaluable patients.
The next most sophisticated prospect, VB-201, in January of this year started dosing clients in a Stage 2 research study. This randomized regulated study will investigate VB-201 as a treatment for COVID-19.
Biopharmas require funds for ongoing research, and Vascular Biogenetics reported finishing 2020 with $30.8 million in cash, cash equivalents, and short-term bank deposits readily available. In a move to increase offered funds, the company made a public offering of 6.9 million shares of typical stock in April. At closing, the offering had raised over $28.3 million gross capital. After deducting expenses, the company will use the profits to money continuing operations.
Oppenheimer’s 5-star expert Kevin DeGeeter is bullish on VBLT, especially with the OVAL research study continuing “on track.”.
” Stage III OVAL research study of VB-111 for treatment of platinum-resistant ovarian cancer demonstrates improvement in ORR in 2nd interim analysis that translates into a total survival advantage. The business’s previous financial investment in commercial-scale manufacturing allows VBLT to secure attractive partnering/takeover economics in spite of the fairly modest size of the innovative ovarian cancer market,” DeGeeter believed.
The analyst included, “Our separated outlook for VBLT is based in big procedure on prospective to engage FDA relating to regulatory filing based on PFS in 2H22 vs. main endpoint of OS (2H23). We see 6-plus months of PFS as a successful outcome. Based on a disappointing upgrade for Mersana’s XMT-1536 in January, we now view VB-111 too positioned to be prospective brand-new SOC in r/r platinum-resistant ovarian cancer clients that have actually likewise failed previous Avastin therapy.”.
To this end, DeGeeter rates VBLT an Outperform (i.e. Buy), and sets a $5 cost target that suggests the stock will grow 163% from the current share cost of $1.91. (To view DeGeeter’s performance history, click on this link).
DeGeeter’s coworkers are also pounding the table on VBLT. Only Purchase ratings, 4, in truth, have actually been released in the last three months, so the consensus ranking is a Strong Buy. With an average rate target of $5– matching DeGeeter’s above– VBLT reveals space for a robust advantage in the next 12 months. (See VBLT stock analysis on TipRanks).
To discover excellent concepts for penny stocks trading at appealing assessments, see TipRanks’ Finest Stocks to Purchase, a recently released tool that unifies all of TipRanks’ equity insights.
Disclaimer: The opinions expressed in this article are entirely those of the featured experts. The content is meant to be utilized for informational functions just. It is extremely essential to do your own analysis before making any financial investment.